TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17p

Leukemia. 2010 Jan;24(1):216-9. doi: 10.1038/leu.2009.189. Epub 2009 Sep 17.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chromosome Deletion*
  • Chromosomes, Human, Pair 17*
  • Gene Dosage*
  • Genes, p53*
  • Humans
  • Leukemia, Myeloid, Acute / genetics*
  • Loss of Heterozygosity*
  • Mutation*
  • Myelodysplastic Syndromes / genetics*